Was a Drop in CRISPR Firms’ Stock Warranted?

A study of off-target effects that sparked fear among investors of genome-editing companies receives methodological criticisms.

| 5 min read

Register for free to listen to this article
Listen with Speechify
0:00
5:00
Share

ISTOCK, VCHALUpdate (June 15): Yesterday (June 14) Nature Methods posted an editorial note on the paper in question: “Readers are alerted that the conclusions of this paper are subject to criticisms that are being considered by editors. A further editorial response will follow the resolution of these issues.” —Jef Akst

Last week, a study made headlines worldwide with its claim that the CRISPR-Cas9 genome-editing technique is more error prone than expected. In response, some investors chose to sell their shares in CRISPR-based biotech firms and stock values dipped by up to 15 percent for some companies.

But do the findings in the latest CRISPR report justify all this panic?

Scientists and companies developing CRISPR-based treatments say no, pointing to flaws in the evidence. Furthermore, the need to screen for off-target mutations and optimize techniques long before they are presented to regulatory bodies is something CRISPR insiders are well aware of, says Ritu Baral, a biotechnology stock analyst from the investment firm Cowen. “All of these things are happening behind the scenes, but non-specialists and retail ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member? Login Here

Keywords

Meet the Author

  • Claire Asher

    This person does not yet have a bio.
Share
3D illustration of a gold lipid nanoparticle with pink nucleic acid inside of it. Purple and teal spikes stick out from the lipid bilayer representing polyethylene glycol.
February 2025, Issue 1

A Nanoparticle Delivery System for Gene Therapy

A reimagined lipid vehicle for nucleic acids could overcome the limitations of current vectors.

View this Issue
Enhancing Therapeutic Antibody Discovery with Cross-Platform Workflows

Enhancing Therapeutic Antibody Discovery with Cross-Platform Workflows

sartorius logo
Considerations for Cell-Based Assays in Immuno-Oncology Research

Considerations for Cell-Based Assays in Immuno-Oncology Research

Lonza
An illustration of animal and tree silhouettes.

From Water Bears to Grizzly Bears: Unusual Animal Models

Taconic Biosciences
Sex Differences in Neurological Research

Sex Differences in Neurological Research

bit.bio logo

Products

Photo of a researcher overseeing large scale production processes in a laboratory.

Scaling Lentiviral Vector Manufacturing for Optimal Productivity

Thermo Fisher Logo
Collage-style urban graphic of wastewater surveillance and treatment

Putting Pathogens to the Test with Wastewater Surveillance

An illustration of an mRNA molecule in front of a multicolored background.

Generating High-Quality mRNA for In Vivo Delivery with lipid nanoparticles

Thermo Fisher Logo
Tecan Logo

Tecan introduces Veya: bringing digital, scalable automation to labs worldwide